Evidence map›Paper›PMID 31787108›Full record

Trial reportAddiction science & clinical practice2019

Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine.

Thomas R Blue, Michael S Gordon, Robert P Schwartz, Kathryn Couvillion, Frank J Vocci, Terrence T Fitzgerald, Kevin E O'Grady

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Addiction science & clinical practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00574067 (Buprenorphine for Prisoners), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00574067 phase3completednot on this map

Buprenorphine for Prisoners

TypeinterventionalSponsorFriends Research Institute, Inc.Ran2008 to 2013Enrolled213ConditionsHeroin AddictionArmsBuprenorphine +OTP, Buprenorphine +CHC, Counseling +OTP, Counseling +CHC
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Introduction to the special issue.Addiction science & clinical practice · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Thomas R BlueFriends Research Institute Inc., 1040 Park Avenue, Suite 103, Baltimore, MD, 21201, USA. tblue@friendsresearch.org.
Michael S GordonFriends Research Institute Inc., 1040 Park Avenue, Suite 103, Baltimore, MD, 21201, USA.
Robert P SchwartzFriends Research Institute Inc., 1040 Park Avenue, Suite 103, Baltimore, MD, 21201, USA.
Kathryn CouvillionFriends Research Institute Inc., 1040 Park Avenue, Suite 103, Baltimore, MD, 21201, USA.
Frank J VocciFriends Research Institute Inc., 1040 Park Avenue, Suite 103, Baltimore, MD, 21201, USA.
Terrence T FitzgeraldGlenwood Life Counseling Center, 516 Glenwood Avenue, Baltimore, MD, 21212, USA.
Kevin E O'GradyDepartment of Psychology, University of Maryland, College Park, 4094 Campus Drive, College Park, MD, 20742, USA.
Friends Research Institute · USCounseling Center · USUniversity of Maryland, College Park · US

Funding

Buprenorphine for PrisonersR01DA021579 · NIDA · FRIENDS RESEARCH INSTITUTE, INC. · PI KINLOCK, TIMOTHY W · 2007 to 2011
$2.7M
NIDA NIH HHS R01 DA021579
6 · The paper itself

Abstract

backgroundIt has been estimated that approximately 15% of people who are incarcerated in the US have histories of opioid use disorder. Relapse to opioid use after release from prison poses a serious risk of HIV infection. Prison-initiated buprenorphine may help to reduce HIV infection given the association between opioid use and HIV-risk behaviors.

methodsThe present study is a secondary analysis of longitudinal data gathered from a randomized controlled trial of buprenorphine-naloxone for people who were incarcerated (N = 211) between 2008 and 2012. It compares the impact of assignment to initiate buprenorphine in prison (N = 106 randomized, N = 104 analyzed) versus in the community (N = 107 randomized, N = 107 analyzed) and whether or not participants entered community treatment on the frequency of HIV-risk behaviors in the 12 months following release from prison. Data were analyzed hierarchically and for each outcome variable, a multilevel, over-dispersed Poisson model was fit to the data. Outcome variables were the number of times the following behaviors occurred in the last 30 days: (1) having sex without a condom (2) injecting drugs (3) using unsterilized needles, and (4) sharing injection paraphernalia.

resultsParticipants assigned to begin buprenorphine in the community experienced a greater decrease in injection drug use over time compared to participants assigned to begin buprenorphine in prison. There were no significant associations between treatment assignment or community treatment entry and instances of having sex without a condom, sharing injection paraphernalia, or using unsterilized needles.

conclusionsOverall, the present study did not find support for the initiation of buprenorphine in prison (as opposed to the community) as a means to reduce incidences of HIV-risk behaviors. Avenues for future research in the nexus of HIV-risk reduction, criminal justice, and pharmacotherapy are discussed. Trial registration This study was supported by the National Institute on Drug Abuse (NIDA), Buprenorphine for Prisoners (PI: Kinlock; R01DA021579). ClinicalTrials.gov identifier: NCT00574067.

Indexed as

PrisonsRisk-TakingAdolescentAdultBuprenorphine, Naloxone Drug CombinationFemaleHIV InfectionsHumansMaleNeedle SharingOpioid-Related DisordersSocioeconomic FactorsSubstance Abuse, IntravenousUnited StatesUnsafe SexYoung AdultBuprenorphine, Naloxone Drug CombinationBuprenorphineCorrectional settingsHiv-risk behaviorOpioid use disorderPrison

Identifiers

PMID31787108
PMCPMC6886176
OpenAlexW2991026782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.